Comparative Pharmacology
Head-to-head clinical analysis: COMTAN versus TASMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMTAN versus TASMAR.
COMTAN vs TASMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which inhibits the metabolism of levodopa to 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa in the brain.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which increases the bioavailability of levodopa by reducing its peripheral metabolism.
200 mg orally once daily, increased to 200 mg three times daily as tolerated, with each dose of levodopa/carbidopa; maximum 200 mg per dose.
100 mg orally three times daily; maximum 200 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 0.4 to 0.7 hours (mean 0.7 hours) in plasma, but the pharmacodynamic half-life (COMT inhibition) is longer, about 2-4 hours, supporting thrice-daily dosing.
Terminal elimination half-life is 2–3 hours in healthy volunteers; clinically, this short half-life necessitates three-times-daily dosing to maintain COMT inhibition, though peripheral COMT activity recovers within 4–6 hours.
Primarily fecal (90%) as unchanged drug; renal excretion accounts for approximately 10%, mostly as glucuronide conjugates.
Primarily hepatic metabolism (glucuronidation and methylation), with approximately 40% of the dose excreted in urine as metabolites and <0.5% as unchanged drug; about 50% is eliminated in feces via biliary excretion.
Category C
Category C
COMT Inhibitor
COMT Inhibitor